Accord Logo

Intended for UK patients and members of the public

Additional Information

Please note that some products on this page share the same name. Please take extra care to make sure the PL number of your medicine matches the PL number of the medicine you select on this page. The PL number can be found on your medicine bottle or carton. If you are unsure, please contact your pharmacist.

Lenalidomide Capsules

Active Ingredients

Product Documentation

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Lenalidomide Accord 10mg Hard Capsules

PL Number:
EU/1/18/1316/001-014
MA Holder:
Accord Healthcare S.L.U
Product Classification:
POM
Product Status:
Active

Product Documentation

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Lenalidomide Accord 15mg Hard Capsules

PL Number:
EU/1/18/1316/001-014
MA Holder:
Accord Healthcare S.L.U
Product Classification:
POM
Product Status:
Active

Product Documentation

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Lenalidomide Accord 20mg Hard Capsules

PL Number:
PLGB 20075/1296
MA Holder:
Accord Healthcare Limited
Product Classification:
POM
Product Status:
Active

Product Documentation

  • View Summary of Product Characteristics (SmPC- Lenalidomide Accord 20 mg Hard Capsules)

    Last updated on this site: 27 Jun 2023

    Description of update:

    1) To update sections 4.2 and 4.4 of SmPC and section 2 of leaflet in-line with the reference product (Revlimid; 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg Capsule, hard; EU procedure reference number: EMEA/H/C/000717/II/0122; MAH: Bristol Myers Squibb Pharma EEIG).

    2) To update section 5.1 of the SmPC in-line with the reference product (Revlimid; 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg Capsule, hard; EU procedure reference number: EMEA/H/C/000717/II/0124; MAH: Bristol Myers Squibb Pharma EEIG). Additionally, editorial updates have been made to sections 4.2, 4.4, 4.5, 4.8, 5.1 of SmPC and section 2, 3 and 4 of PIL in line with reference products.

    SmPC sections updated: 4.2, 4.4, 4.6, 4.8, 5.1, 10.

    View change history
  • View Patient Information Leaflet (PIL- Lenalidomide Accord 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg Hard Capsules)

    Last updated on this site: 27 Jun 2023

    Description of update:

    1) To update sections 4.2 and 4.4 of SmPC and section 2 of leaflet in-line with the reference product (Revlimid; 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg Capsule, hard; EU procedure reference number: EMEA/H/C/000717/II/0122; MAH: Bristol Myers Squibb Pharma EEIG).

    2) To update section 5.1 of the SmPC in-line with the reference product (Revlimid; 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg Capsule, hard; EU procedure reference number: EMEA/H/C/000717/II/0124; MAH: Bristol Myers Squibb Pharma EEIG). Additionally, editorial updates have been made to sections 4.2, 4.4, 4.5, 4.8, 5.1 of SmPC and section 2, 3 and 4 of PIL in line with reference products.

    PIL sections updated: 2, 3, 6.

    View change history

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Lenalidomide Accord 20mg Hard Capsules

PL Number:
EU/1/18/1316/001-014
MA Holder:
Accord Healthcare S.L.U
Product Classification:
POM
Product Status:
Active

Product Documentation

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Lenalidomide Accord 2.5mg Hard Capsules

PL Number:
PLGB 20075/1291
MA Holder:
Accord Healthcare Limited
Product Classification:
POM
Product Status:
Active

Product Documentation

  • View Summary of Product Characteristics (SmPC- Lenalidomide Accord 2.5 mg Hard Capsules)

    Last updated on this site: 27 Jun 2023

    Description of update:

    1) To update sections 4.2 and 4.4 of SmPC and section 2 of leaflet in-line with the reference product (Revlimid; 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg Capsule, hard; EU procedure reference number: EMEA/H/C/000717/II/0122; MAH: Bristol Myers Squibb Pharma EEIG).

    2) To update section 5.1 of the SmPC in-line with the reference product (Revlimid; 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg Capsule, hard; EU procedure reference number: EMEA/H/C/000717/II/0124; MAH: Bristol Myers Squibb Pharma EEIG). Additionally, editorial updates have been made to sections 4.2, 4.4, 4.5, 4.8, 5.1 of SmPC and section 2, 3 and 4 of PIL in line with reference products.

    SmPC sections updated: 4.2, 4.4, 4.6, 4.8, 5.1, 10.

    View change history
  • View Patient Information Leaflet (PIL- Lenalidomide Accord 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg Hard Capsules)

    Last updated on this site: 27 Jun 2023

    Description of update:

    1) To update sections 4.2 and 4.4 of SmPC and section 2 of leaflet in-line with the reference product (Revlimid; 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg Capsule, hard; EU procedure reference number: EMEA/H/C/000717/II/0122; MAH: Bristol Myers Squibb Pharma EEIG).

    2) To update section 5.1 of the SmPC in-line with the reference product (Revlimid; 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg Capsule, hard; EU procedure reference number: EMEA/H/C/000717/II/0124; MAH: Bristol Myers Squibb Pharma EEIG). Additionally, editorial updates have been made to sections 4.2, 4.4, 4.5, 4.8, 5.1 of SmPC and section 2, 3 and 4 of PIL in line with reference products.

    PIL sections updated: 2, 3, 6.

    View change history

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Lenalidomide Accord 2.5mg Hard Capsules

PL Number:
EU/1/18/1316/001-014
MA Holder:
Accord Healthcare S.L.U
Product Classification:
POM
Product Status:
Active

Product Documentation

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Lenalidomide Accord 25mg Hard Capsules

PL Number:
EU/1/18/1316/001-014
MA Holder:
Accord Healthcare S.L.U
Product Classification:
POM
Product Status:
Active

Product Documentation

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Lenalidomide Accord 25mg Hard Capsules

PL Number:
PLGB 20075/1297
MA Holder:
Accord Healthcare Limited
Product Classification:
POM
Product Status:
Active

Product Documentation

  • View Summary of Product Characteristics (SmPC- Lenalidomide Accord 25 mg Hard Capsules)

    Last updated on this site: 27 Jun 2023

    Description of update:

    1) To update sections 4.2 and 4.4 of SmPC and section 2 of leaflet in-line with the reference product (Revlimid; 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg Capsule, hard; EU procedure reference number: EMEA/H/C/000717/II/0122; MAH: Bristol Myers Squibb Pharma EEIG).

    2) To update section 5.1 of the SmPC in-line with the reference product (Revlimid; 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg Capsule, hard; EU procedure reference number: EMEA/H/C/000717/II/0124; MAH: Bristol Myers Squibb Pharma EEIG). Additionally, editorial updates have been made to sections 4.2, 4.4, 4.5, 4.8, 5.1 of SmPC and section 2, 3 and 4 of PIL in line with reference products.

    SmPC sections updated: 4.2, 4.4, 4.6, 4.8, 5.1, 10.

    View change history
  • View Patient Information Leaflet (PIL- Lenalidomide Accord 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg Hard Capsules)

    Last updated on this site: 27 Jun 2023

    Description of update:

    1) To update sections 4.2 and 4.4 of SmPC and section 2 of leaflet in-line with the reference product (Revlimid; 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg Capsule, hard; EU procedure reference number: EMEA/H/C/000717/II/0122; MAH: Bristol Myers Squibb Pharma EEIG).

    2) To update section 5.1 of the SmPC in-line with the reference product (Revlimid; 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg Capsule, hard; EU procedure reference number: EMEA/H/C/000717/II/0124; MAH: Bristol Myers Squibb Pharma EEIG). Additionally, editorial updates have been made to sections 4.2, 4.4, 4.5, 4.8, 5.1 of SmPC and section 2, 3 and 4 of PIL in line with reference products.

    PIL sections updated: 2, 3, 6.

    View change history

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Lenalidomide Accord 5mg Hard Capsules

PL Number:
EU/1/18/1316/001-014
MA Holder:
Accord Healthcare S.L.U
Product Classification:
POM
Product Status:
Active

Product Documentation

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Lenalidomide Accord 7.5mg Hard Capsules

PL Number:
EU/1/18/1316/001-014
MA Holder:
Accord Healthcare S.L.U
Product Classification:
POM
Product Status:
Active

Product Documentation

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

General FAQs

For any further assistance, please get in touch.

Contact Us Report a side effect or product complaint

View product information as a: